ARTICLE | Clinical News
Basilea preclinical data
May 16, 2011 7:00 AM UTC
In vitro, 4 mg/L BAL30072 was active against 60% of 78 isolates of Gram-negative bacteria containing New Delhi metallo-beta-lactamase 1 (NDM-1) vs. <10% for aztreonam, ceftazidime and meropenem. Addit...